Unreliable commercial lab kits may be hindering fight against cancer
A doctor’s ability to test for cancer in its earlier stages often determines a patient’s chances of survival. Pancreatic ductal adenocarcinoma (PDAC) is a grim example of this. The majority of patients live only 3 to 18 months, because current diagnosis methods usually can’t detect PDAC until it is too advanced to respond to treatment. Testing for the right biomarkers — biological molecules whose presence indicates a condition or disease — could be instrumental in the early detection of cancers like PDAC…